Investor Activity Rises as ORIC Pharmaceuticals Sees New Institutional Buys In recent trading, ORIC Pharmaceuticals attracted notable institutional investment, with Natixis acquiring nearly 80,000 shares. The company’s stock opened at $5.19, reflecting a market cap of $368 million. Despite a negative earnings report, analysts expect ORIC to post an annual EPS of -2.17, highlighting continued interest in its oncology pipeline.12